SEARCH: A Study to Compare Different Antibiotics and Different Modes of Fluid Treatment for Children With Severe Pneumonia

Sponsor

University of Oxford (Other)

Overall Status

Suspended

CT.gov ID

NCT04041791

Collaborator

University of Nairobi (Other), London School of Hygiene and Tropical Medicine (Other), National Institute for Health Research, United Kingdom (Other), Department for International Development, United Kingdom (Other), Medical Research Council (Other), Wellcome Trust (Other), Kenya Ministry of Health (Other)

4,392

Enrollment

Location

Arms

41.5

Anticipated Duration (Months)

105.9

Patients Per Site Per Month

Study Details

Study Description

Brief Summary

Pneumonia is one of the top causes of death in children aged below 5. More than 10% of children with severe pneumonia die. We are not sure that the currently recommended antibiotics used in children with pneumonia are the most effective. No studies have been carried out to find out whether children with pneumonia should be given intravenous (IV) fluids or nasogastric (NG) feeds.

The SEARCH trial aims to find out which antibiotics and modes of feeding are the most effective in treating children with severe pneumonia and therefore helping reduce mortality.

Condition or Disease	Intervention/Treatment	Phase
Pneumonia	Drug: Benzyl penicillin Drug: Gentamicin Sulfate Drug: Ceftriaxone Drug: Amoxicillin Clavulanate Other: Intravenous fluid Other: Nasogastric feeds Drug: Ampicillin	Phase 3

Detailed Description

Pneumonia is one of the leading causes of death among young children with more than 10% of children aged under-five with severe pneumonia dying. The World Health Organisation (WHO) guidelines recommend the use of benzyl penicillin plus gentamicin as the standard of care of treatment for severe pneumonia. However, there have been increasing concerns about the effectiveness of the current recommendations.

Some authorities advise against the use of enteral nutrition in severely ill patients due to concerns of compromised respiratory status and risk of aspiration with nasogastric feeding. Evidence to support these concerns is lacking.

This trial aims to find out which antibiotics are the most effective in the treatment of children with severe pneumonia by comparing the current standard of care (benzyl penicillin or ampicillin plus gentamicin) to injectable ceftriaxone and injectable amoxicillin-clavulanic acid. The study will also determine whether providing feeds through a nasogastric tube is superior to intravenous fluid therapy in children with severe pneumonia.

The SEARCH trial will be a multi-site pragmatic randomised controlled trial that will assess the efficacy of both interventions in children admitted with severe pneumonia in a 3x2 factorial design. The sites will be in East Africa.

Data from the trial will be used to inform policy and contribute to guidelines and improve clinical practice in settings where the burden of pneumonia is highest.

Study Design

Study Type:

Interventional

Anticipated Enrollment :

4392 participants

Allocation:

Randomized

Intervention Model:

Factorial Assignment

Masking:

None (Open Label)

Primary Purpose:

Treatment

Official Title:

Supportive Care and Antibiotics for Severe Pneumonia Among Hospitalized Children

Actual Study Start Date :

Aug 19, 2019

Anticipated Primary Completion Date :

Aug 1, 2022

Anticipated Study Completion Date :

Feb 1, 2023

Arms and Interventions

Arm	Intervention/Treatment
Active Comparator: Benzyl penicillin/ampicillin + gentamicin & IV fluids Participants are assigned to receive benzyl penicillin at 50,000 IU/kg every 6 hours or ampicillin 50mg/kg every 8 hours plus gentamicin 7.5 mg/kg once daily given intravenously (IV) or via intramuscular (IM) injection for a minimum of 48 hours and for up to 7 days. Maintenance fluids will be given as a continuous infusion for at least 24 hours.	Drug: Benzyl penicillin Benzyl penicillin is a penicillin antibiotic. Other Names: Medipen Cristapen Drug: Gentamicin Sulfate Gentamicin is an aminoglycoside antibiotic. Other Names: Gentamicin Gentamed Other: Intravenous fluid Maintenance fluids administered for at least 24 hours. Other Names: Hartmann's Solution with 5% dextrose Ringer's Lactate with 5% dextrose Normal Saline with 5% dextrose Drug: Ampicillin Ampicillin is a penicillin-type antibiotic.
Experimental: Ceftriaxone and IV fluids Participants are assigned to receive ceftriaxone at 50 mg/kg every 12 hours given IV or IM for a minimum of 48 hours and for up to 7 days. Intravenous fluids will be given as a continuous infusion for at least 24 hours.	Drug: Ceftriaxone Ceftriaxone is a third generation cephalosporin antibiotic active against a wide range of gram negative and positive bacteria. Other Names: Desefin Other: Intravenous fluid Maintenance fluids administered for at least 24 hours. Other Names: Hartmann's Solution with 5% dextrose Ringer's Lactate with 5% dextrose Normal Saline with 5% dextrose
Experimental: Amoxicillin-clavulanate and IV fluids Participants are assigned to receive amoxicillin clavulanic acid at 30 mg/kg every 8 hours given IV or IM for a minimum of 48 hours and for up to 7 days. Intravenous fluids will be given as a continuous infusion for at least 24 hours.	Drug: Amoxicillin Clavulanate Amoxicillin Clavulanate is a combination of amoxicillin, a β-lactam antibiotic, and potassium clavulanate, a β-lactamase inhibitor. Other Names: Amoxicillin-clavulanic acid Amoxi-clav Amoklavin Co-amoxiclav Other: Intravenous fluid Maintenance fluids administered for at least 24 hours. Other Names: Hartmann's Solution with 5% dextrose Ringer's Lactate with 5% dextrose Normal Saline with 5% dextrose
Experimental: Benzyl penicillin/ampicillin + gentamicin & NG feeds Participants are assigned to receive Benzyl penicillin at 50,000 IU/kg every 6 hours or ampicillin 50mg/kg every 8 hours plus gentamicin 7.5 mg/kg once daily given intravenously (IV) or via intramuscular (IM) injection for a minimum of 48 hours and for up to 7 days. Nasogastric feeds will be given 3 hourly for at least 24 hours.	Drug: Benzyl penicillin Benzyl penicillin is a penicillin antibiotic. Other Names: Medipen Cristapen Drug: Gentamicin Sulfate Gentamicin is an aminoglycoside antibiotic. Other Names: Gentamicin Gentamed Other: Nasogastric feeds Feeds given via nasogastric tube. Feeds may include cow's milk, breast milk, porridge, formula among others. Drug: Ampicillin Ampicillin is a penicillin-type antibiotic.
Experimental: Ceftriaxone and NG feeds Participants are assigned to receive ceftriaxone at 50 mg/kg every 12 hours given IV or IM for up to 7 days. Nasogastric feeds will be given 3 hourly for at least 24 hours.	Drug: Ceftriaxone Ceftriaxone is a third generation cephalosporin antibiotic active against a wide range of gram negative and positive bacteria. Other Names: Desefin Other: Nasogastric feeds Feeds given via nasogastric tube. Feeds may include cow's milk, breast milk, porridge, formula among others.
Experimental: Amoxicillin-clavulanic acid and NG feeds Participants are assigned to receive amoxicillin clavulanic acid at 30 mg/kg every 8 hours given IV or IM for up to 7 days. Nasogastric feeds will be given 3 hourly for at least 24 hours.	Drug: Amoxicillin Clavulanate Amoxicillin Clavulanate is a combination of amoxicillin, a β-lactam antibiotic, and potassium clavulanate, a β-lactamase inhibitor. Other Names: Amoxicillin-clavulanic acid Amoxi-clav Amoklavin Co-amoxiclav Other: Nasogastric feeds Feeds given via nasogastric tube. Feeds may include cow's milk, breast milk, porridge, formula among others.

Outcome Measures

Primary Outcome Measures

Mortality [Up to Day 5]
Mortality of participants receiving any of the injectable antibiotic treatments who die within the first five days of admission measured from source documents, medical records, verbal autopsy or death certificates.

Secondary Outcome Measures

Number of serious adverse events [Up to Day 30]
Serious adverse events that my be likely or definitely related to any of the interventions given to the participants. Serious adverse events include death, a life threatening event, persistent or significant disability or incapacity, hospitalisation or prolonged hospitalisation.
Length of hospitalisation [Through duration of hospitalisation, an average of 5 days]
Total days a participant is admitted or receives inpatient care measured in days using hospital records at the start and end of each admission.
Duration taken to tolerate full fluids by mouth [An average of 3 days]
Number of days it takes for participants to fully tolerate fluids orally.
Mortality 30 days after enrollment [Day 30 post enrollment]
Number of participants who die within 30 days of enrollment into the study measured using source documents, medical records, verbal autopsy or death certificates.

Eligibility Criteria

Criteria

Ages Eligible for Study:

2 Months to 59 Months

Sexes Eligible for Study:

All

Accepts Healthy Volunteers:

Inclusion Criteria:

Age 2 to 59 months.
History of cough or difficulty breathing and signs of severe pneumonia based on WHO 2013 criteria
Admitted to any one of the study hospitals.
Informed consent provided by the parents/guardian.

Exclusion Criteria:

Children presenting in cardiorespiratory arrest requiring emergency basic life support (bag-valve-mask ventilation and/or chest compressions).
Children for whom concurrent condition precludes the use of the first-line antibiotics for severe pneumonia such as readmission or meningitis
Shock due to dehydration or severe dehydration (based on WHO definitions (5)) requiring emergency fluid resuscitation
Known allergy or contraindication to penicillin, gentamicin, ceftriaxone or amoxicillin-clavulanic acid.
Referral from another inpatient facility following treatment with injectable antibiotics for more than 24 hours or because the first-line regimen is considered to have failed
Previously enrolled in the study.
For supportive care intervention (Intravenous fluids versus nasogastric feeds): children with absent gag reflex.
For supportive care intervention (Intravenous fluids versus nasogastric feeds): children unable to maintain oxygen saturations greater 90% on pulse oximetry while receiving supplemental oxygen.
For supportive care intervention (Intravenous fluids versus nasogastric feeds): children with severe acute malnutrition